Tofanib™

Tofacitinib

Presentation

Tofanib™ 5 mg Tablet: Each film coated tablet contains Tofacitinib citrate INN 8.0 mg equivalent to Tofacitinib 5 mg.

Tofanib™ XR Tablet: Each extended release tablet contains Tofacitinib citrate INN 17.77 mg equivalent to Tofacitinib 11 mg.

Description

Tofanib is the citrate salt of Tofacitinib, an inhibitor of Janus Kinase (JAK). JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Tofacitinib modulates the signaling pathway of cytokine at the point of JAKs, preventing the phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. The absolute oral bioavailability of Tofacitinib is 74%. Clearance mechanisms for Tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. The metabolism of Tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19.

Indications

Tofanib is indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It can be used as monotherapy or in combination with methotrexate or other nonbiologic Disease Modifying Antirheumatic Drugs (DMARDs).

Dosage and administration

Adults: The recommended dose is **Tofanib XR 11 mg** once daily or **Tofanib 5 mg** twice daily, given orally with or without food. Swallow the **Tofanib XR** tablet whole and intact. Do not crush, split or chew.

Hepatic and renal impaired patients: In patients with moderate or severe renal insufficiency or moderate hepatic impairment, the recommended dose is Tofanib 5 mg once daily.

Children: The safety and efficacy of **Tofacitinib** in children is not known.

Contraindications

Hypersensitivity to **Tofacitinib** or any other ingredients of this product.**Tofacitinib** is contraindicated in severe liver problems.

Side effects

The most commonly reported side effects are upper respiratory tract infections, headache, diarrhea and nasopharyngitis.

Use in pregnancy and lactation

Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. **Tofacitinib** should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Tofacitinib is excreted in human milk. Decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother.

Drug interactions

Tofacitinib exposure is increased when co-administered with potent inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) and with medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g, fluconazole). The dosage should be reduced to 5 mg once daily.

The clinical response of Tofacitinib may be reduced when co-administered with potent inducers of CYP3A4 (e.g., rifampin). Immunosuppression may occur when co-administered with potent immunosuppressive drugs (e.g, azathioprine, tacrolimus, cyclosporine).

Warnings and precautions

Tofacitinib should not be initiated in patients with an active infection, including localized infections. The risks and benefits of treatment should be considered prior to initiating **Tofacitinib** in patients with previous history or risk of tuberculosis or serious infections. Laboratory monitoring is recommended for liver enzymes and lipids. **Tofacitinib** should not be initiated in patients with a lymphocyte count less than 500 cells/mm^3, an absolute neutrophil count (ANC) less than 1000 cells/mm^3, or who have hemoglobin levels less than 9 g/dL. Live vaccines should not be given concurrently with **Tofacitinib**.

Overdosage

There is no experience with overdose of Tofacitinib. According to Pharmacokinetic data, more than 95% of the administered dose (100 mg single dose) in healthy volunteers is expected to be eliminated within 24 hours. There is no specific antidote for overdose with Tofacitinib. In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions.

Storage

Store in a cool (below 30^0C) and dry place. Protect from light and keep out of reach of children.

Packaging

Tofanib™ 5 mg Tablet: Each box contains 1 x 10 tablets in Alu-Alu blister strip.

Tofanib™ XR Tablet: Each box contains 1 x 10 tablets in Alu-Alu blister strip.

Manufactured by

GLOBE PHARMACEUTICALS LTD.
NOAKHALI, BANGLADESH